Rachel L Taylor1, Gavin Arno2, James A Poulter3, Kamron N Khan4, Jiten Morarji5, Sarah Hull6, Nikolas Pontikos7, Antonio Rueda Martin8, Katherine R Smith8, Manir Ali3, Carmel Toomes3, Martin McKibbin4, Jill Clayton-Smith1, Stephanie Grunewald9, Michel Michaelides6, Anthony T Moore10, Alison J Hardcastle6, Chris F Inglehearn3, Andrew R Webster6, Graeme C Black1. 1. Genomic Medicine, Division of Evolution and Genomic Sciences, Faculty of Biology, Medicines and Health, University of Manchester, Manchester Academic Health Science Centre (MAHSC), Manchester, England2Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, MAHSC, Saint Mary's Hospital, Manchester, England. 2. UCL Institute of Ophthalmology, University College London, London, England. 3. Section of Ophthalmology and Neuroscience, Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, England. 4. Section of Ophthalmology and Neuroscience, Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, England 5Department of Ophthalmology, St. James's University Hospital, Leeds, England. 5. Manchester Royal Eye Hospital, Manchester Academic Health Science Centre, Central Manchester Foundation Trust, Manchester, England. 6. UCL Institute of Ophthalmology, University College London, London, England 7Moorfields Eye Hospital, London, England. 7. UCL Genetics Institute, University College London, London, England. 8. Genomics England, Queen Mary University of London, London, England. 9. Metabolic Unit, Great Ormond Street Hospital, London, England11Institute for Child Health, University College London, London, England. 10. UCL Institute of Ophthalmology, University College London, London, England 12Department of Ophthalmology, University of California, San Francisco, Medical School, San Francisco.
Abstract
Importance: Steroid 5α-reductase type 3 congenital disorder of glycosylation (SRD5A3-CDG) is a rare disorder of N-linked glycosylation. Its retinal phenotype is not well described but could be important for disease recognition because it appears to be a consistent primary presenting feature. Objective: To investigate a series of patients with the same mutation in the SRD5A3 gene and thereby characterize its retinal manifestations and other associated features. Design, Setting and Participants: Seven affected individuals from 4 unrelated families with early-onset retinal dystrophy as a primary manifestation underwent comprehensive ophthalmic assessment, including retinal imaging and electrodiagnostic testing. Developmental and systemic findings were also recorded. Molecular genetic approaches, including targeted next-generation sequencing, autozygosity mapping, and apex microarray, were tried to reach a diagnosis; all participants were mutation negative. Whole-exome sequencing or whole-genome sequencing was used to identify the causative variant. Biochemical profiling was conducted to confirm a CDG type I defect. Patient phenotype data were collected over the course of ophthalmic follow-up, spanning a period of 20 years, beginning March 20, 1997, through September 15, 2016. Main Outcomes and Measures: Detailed clinical phenotypes as well as genetic and biochemical results. Results: The cohort consisted of 7 participants (5 females and 2 males) whose mean (SD) age at the most recent examination was 17.1 (3.9) years and who were all of South Asian ethnicity. Whole-exome sequencing and whole-genome sequencing identified the same homozygous SRD5A3 c.57G>A, p.(Trp19Ter) variant as the underlying cause of early-onset retinal dystrophy in each family. Detailed ocular phenotyping identified early-onset (aged ≤3 years) visual loss (mean [SD] best-corrected visual acuity, +0.95 [0.34] logMAR [20/180 Snellen]), childhood-onset nyctalopia, myopia (mean [SD] refractive error, -6.71 [-4.22]), and nystagmus. Six of the 7 patients had learning difficulties and psychomotor delay. Fundus autofluorescence imaging and optical coherence tomographic scans were abnormal in all patients, and electrodiagnostic testing revealed rod and cone dysfunction in the 5 patients tested. Conclusions and Relevance: Mutations in the SRD5A3 gene may cause early-onset retinal dystrophy, a previously underdescribed feature of the SRD5A3-CDG disorder that is progressive and may lead to serious visual impairment. SRD5A3 and other glycosylation disorder genes should be considered as a cause of retinal dystrophy even when systemic features are mild. Further delineation of SRD5A3-associated eye phenotypes can help inform genetic counseling for prognostic estimation of visual loss and disease progression.
Importance: Steroid 5α-reductase type 3 congenital disorder of glycosylation (SRD5A3-CDG) is a rare disorder of N-linked glycosylation. Its retinal phenotype is not well described but could be important for disease recognition because it appears to be a consistent primary presenting feature. Objective: To investigate a series of patients with the same mutation in the SRD5A3 gene and thereby characterize its retinal manifestations and other associated features. Design, Setting and Participants: Seven affected individuals from 4 unrelated families with early-onset retinal dystrophy as a primary manifestation underwent comprehensive ophthalmic assessment, including retinal imaging and electrodiagnostic testing. Developmental and systemic findings were also recorded. Molecular genetic approaches, including targeted next-generation sequencing, autozygosity mapping, and apex microarray, were tried to reach a diagnosis; all participants were mutation negative. Whole-exome sequencing or whole-genome sequencing was used to identify the causative variant. Biochemical profiling was conducted to confirm a CDG type I defect. Patient phenotype data were collected over the course of ophthalmic follow-up, spanning a period of 20 years, beginning March 20, 1997, through September 15, 2016. Main Outcomes and Measures: Detailed clinical phenotypes as well as genetic and biochemical results. Results: The cohort consisted of 7 participants (5 females and 2 males) whose mean (SD) age at the most recent examination was 17.1 (3.9) years and who were all of South Asian ethnicity. Whole-exome sequencing and whole-genome sequencing identified the same homozygous SRD5A3 c.57G>A, p.(Trp19Ter) variant as the underlying cause of early-onset retinal dystrophy in each family. Detailed ocular phenotyping identified early-onset (aged ≤3 years) visual loss (mean [SD] best-corrected visual acuity, +0.95 [0.34] logMAR [20/180 Snellen]), childhood-onset nyctalopia, myopia (mean [SD] refractive error, -6.71 [-4.22]), and nystagmus. Six of the 7 patients had learning difficulties and psychomotor delay. Fundus autofluorescence imaging and optical coherence tomographic scans were abnormal in all patients, and electrodiagnostic testing revealed rod and cone dysfunction in the 5 patients tested. Conclusions and Relevance: Mutations in the SRD5A3 gene may cause early-onset retinal dystrophy, a previously underdescribed feature of the SRD5A3-CDG disorder that is progressive and may lead to serious visual impairment. SRD5A3 and other glycosylation disorder genes should be considered as a cause of retinal dystrophy even when systemic features are mild. Further delineation of SRD5A3-associated eye phenotypes can help inform genetic counseling for prognostic estimation of visual loss and disease progression.
Authors: Neringa Jurkute; Francesca Cancellieri; Lisa Pohl; Catherina H Z Li; Robert A Heaton; Janine Reurink; James Bellingham; Mathieu Quinodoz; Georgia Yioti; Maria Stefaniotou; Marianna Weener; Theresia Zuleger; Tobias B Haack; Katarina Stingl; Carel B Hoyng; Omar A Mahroo; Iain Hargreaves; F Lucy Raymond; Michel Michaelides; Carlo Rivolta; Susanne Kohl; Susanne Roosing; Andrew R Webster; Gavin Arno Journal: NPJ Genom Med Date: 2022-10-20 Impact factor: 6.083
Authors: Neringa Jurkute; Priya D Shanmugarajah; Marios Hadjivassiliou; Jenny Higgs; Miodrag Vojcic; Iain Horrocks; Yann Nadjar; Valerie Touitou; Guy Lenaers; Roy Poh; James Acheson; Anthony G Robson; F Lucy Raymond; Mary M Reilly; Patrick Yu-Wai-Man; Anthony T Moore; Andrew R Webster; Gavin Arno Journal: Invest Ophthalmol Vis Sci Date: 2021-05-03 Impact factor: 4.799
Authors: Neringa Jurkute; Costin Leu; Hans-Martin Pogoda; Gavin Arno; Anthony G Robson; Gudrun Nürnberg; Janine Altmüller; Holger Thiele; Susanne Motameny; Mohammad Reza Toliat; Kate Powell; Wolfgang Höhne; Michel Michaelides; Andrew R Webster; Anthony T Moore; Matthias Hammerschmidt; Peter Nürnberg; Patrick Yu-Wai-Man; Marcela Votruba Journal: Ann Neurol Date: 2019-07-31 Impact factor: 11.274
Authors: Rachel L Taylor; James A Poulter; Susan M Downes; Martin McKibbin; Kamron N Khan; Chris F Inglehearn; Andrew R Webster; Alison J Hardcastle; Michel Michaelides; Paul N Bishop; Simon J Clark; Graeme C Black Journal: Ophthalmology Date: 2019-03-21 Impact factor: 12.079
Authors: James A Poulter; Molly S C Gravett; Rachel L Taylor; Kaoru Fujinami; Julie De Zaeytijd; James Bellingham; Atta Ur Rehman; Takaaki Hayashi; Mineo Kondo; Abdur Rehman; Muhammad Ansar; Dan Donnelly; Carmel Toomes; Manir Ali; Elfride De Baere; Bart P Leroy; Nigel P Davies; Robert H Henderson; Andrew R Webster; Carlo Rivolta; Christina Zeitz; Omar A Mahroo; Gavin Arno; Graeme C M Black; Martin McKibbin; Sarah A Harris; Kamron N Khan; Chris F Inglehearn Journal: Hum Mutat Date: 2020-11-30 Impact factor: 4.700
Authors: Riccardo Sangermano; Iris Deitch; Virginie G Peter; Rola Ba-Abbad; Emily M Place; Erin Zampaglione; Naomi E Wagner; Anne B Fulton; Luisa Coutinho-Santos; Boris Rosin; Vincent Dunet; Ala'a AlTalbishi; Eyal Banin; Ana Berta Sousa; Mariana Neves; Anna Larson; Mathieu Quinodoz; Michel Michaelides; Tamar Ben-Yosef; Eric A Pierce; Carlo Rivolta; Andrew R Webster; Gavin Arno; Dror Sharon; Rachel M Huckfeldt; Kinga M Bujakowska Journal: NPJ Genom Med Date: 2021-06-29 Impact factor: 8.617